The Endocannabinoid System in Parkinsons Disease

Author(s): Massimiliano Di Filippo, Barbara Picconi, Alessandro Tozzi, Veronica Ghiglieri, Aroldo Rossi, Paolo Calabresi

Journal Name: Current Pharmaceutical Design

Volume 14 , Issue 23 , 2008

Become EABM
Become Reviewer
Call for Editor


Parkinsons disease (PD) is a chronic and progressive neurodegenerative disorder of largely unknown etiology caused by a pathological cascade resulting in the degeneration of midbrain dopaminergic neurons of the substantia nigra pars compacta (SNpc) projecting to the nucleus striatum, the main input station of the basal ganglia neuronal circuit. The components of the endocannabinoid (ECB) system are highly expressed at different levels in the basal ganglia neural circuit where they bidirectionally interact with dopaminergic, glutamatergic and GABAergic signaling systems. In particular, at synapses linking cortical and striatal neurons, endocannabinoids (ECBs) are known to critically modulate synaptic transmission and to mediate the induction of a particular form of synaptic plasticity, the long-term depression. The evidence that ECBs play a central role in regulating basal ganglia physiology and motor function and the profound modifications occurring in ECB signaling after dopamine depletion in both experimental models of PD and patients suffering from the disease, provide support for the development of pharmacological compounds targeting the ECB system as symptomatic and neuroprotective therapeutic strategies for PD.

Keywords: Parkinson's disease, endocannabinoids, synaptic plasticity, neuroinflammation

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [2337 - 2346]
Pages: 10
DOI: 10.2174/138161208785740072
Price: $65

Article Metrics

PDF: 21